Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Oncoinvent

Less than 1K followers

ONCIN

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
23.04M
EBIT %
-687.2 %
P/E
-
Dividend yield-%
-
Financial calendar
27.8
2026

Interim report Q2'26

All
Press releases
ShowingAll content types

Regulatory press release29.10.2025, 17.38

Oncoinvent AS: Merger of BerGenBio and Oncoinvent completed

Oncoinvent
Regulatory press release29.10.2025, 15.16

Oncoinvent AS: Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies

Oncoinvent
Regulatory press release29.10.2025, 07.00

Oncoinvent AS: BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent

Oncoinvent

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release24.10.2025, 07.59

Oncoinvent AS: BerGenBio and Oncoinvent - Key Dates for Completion of Merger

Oncoinvent
Regulatory press release20.10.2025, 10.00

ONCIN: Financial calendar

Oncoinvent
Regulatory press release08.10.2025, 07.00

Oncoinvent AS: Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer

Oncoinvent
Regulatory press release29.08.2025, 07.00

Oncoinvent AS: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement

Oncoinvent
Regulatory press release27.08.2025, 07.00

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

Oncoinvent
Regulatory press release22.08.2025, 12.22

Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 August 2025

Oncoinvent
Regulatory press release04.08.2025, 13.53

Oncoinvent AS: Oncoinvent shareholders approve the merger plan with BerGenBio

Oncoinvent
Regulatory press release03.07.2025, 15.45

Oncoinvent ASA: Notice of Extraordinary General Meeting

Oncoinvent
Regulatory press release30.06.2025, 22.11

Oncoinvent AS: Announcement of fully underwritten rights issue

Oncoinvent
Regulatory press release30.06.2025, 22.01

Oncoinvent AS: BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue

Oncoinvent
Regulatory press release18.06.2025, 08.01

Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Oncoinvent
Regulatory press release18.06.2025, 07.00

ONCIN: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Oncoinvent
Regulatory press release14.05.2025, 14.39

ONCIN: Minutes from the annual general meeting 2025

Oncoinvent
Regulatory press release30.04.2025, 13.41

ONCIN: Notice of Annual General Meeting

Oncoinvent
Regulatory press release28.04.2025, 20.22

Oncoinvent ASA: Annual Report 2024

Oncoinvent
Regulatory press release28.04.2025, 08.05

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

Oncoinvent
Regulatory press release28.04.2025, 08.00

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Oncoinvent